Wechselwirkungen von Tabak und Rauchen

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3) ] . (Fachinformation zu Abrocitinib, Boxed Warning (umrahmter Warnhinweis))

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. (Fachinformation zu Baricitinib, Boxed Warning (umrahmter Warnhinweis))

Instruct the patient the avoid fire, flame, and smoking during and immediately following application. (Fachinformation zu Calcipotriol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. (Fachinformation zu Desogestrel und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (Fachinformation zu Drospirenon und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. (Fachinformation zu Econazol, Warnhinweise und Vorsichtsmaßnahmen)

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). (Fachinformation zu Erlotinib, Arzneimittelwechselwirkungen)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (Fachinformation zu Estradiol und Dienogest, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. (Fachinformation zu Etonogestrel und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. (Fachinformation zu Etynodioldiacetat und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. (Fachinformation zu Levonorgestrel und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. (Fachinformation zu Nitroprussidnatrium, Gegenanzeigen)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI |GTE 30 kg/m2 • Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. (Fachinformation zu Norelgestromin und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. (Fachinformation zu Norethisteron und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. ● Mono-Linyah is contraindicated in women over 35 years old who smoke. (Fachinformation zu Norgestimat und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (Fachinformation zu Norgestrel und Ethinylestradiol, Boxed Warning (umrahmter Warnhinweis))

Therefore, patients being treated with phenelzine sulfate should avoid high protein food that has undergone protein breakdown by aging, fermentation, pickling, smoking, or bacterial contamination. (Fachinformation zu Phenelzin, Gegenanzeigen)

Patients who are current or past smokers are at additional increased risk. (Fachinformation zu Tofacitinib, Boxed Warning (umrahmter Warnhinweis))

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (Fachinformation zu Upadacitinib, Boxed Warning (umrahmter Warnhinweis))

In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with CHANTIX compared to placebo. (Fachinformation zu Vareniclin, Warnhinweise und Vorsichtsmaßnahmen)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (Fachinformation zu Abacavir, Warnhinweise und Vorsichtsmaßnahmen)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (Fachinformation zu Abacavir und Lamivudin, Warnhinweise und Vorsichtsmaßnahmen)

When receiving intravenous ORENCIA, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods. (Fachinformation zu Abatacept, Arzneimittelwechselwirkungen)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

…elevations for longer periods Hypothyroidism Liver disease; cirrhosis, acute hepatitis Reduced renal function in infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline… (Fachinformation zu Aminophyllin, Warnhinweise)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Budesonid, Warnhinweise und Vorsichtsmaßnahmen)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (Fachinformation zu Budesonid und Formoterol, Warnhinweise und Vorsichtsmaßnahmen)

Monitoring of blood pressure is recommended in patients who receive the combination of bupropion and nicotine replacement. (Fachinformation zu Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Celecoxib, Warnhinweise und Vorsichtsmaßnahmen)

Cigarette Smoking (CYP1A2 Inducer) In healthy male heavy smokers, the mean quinine AUC following a single 600 mg dose was 44% lower, the mean C max was 18% lower, and the elimination half-life was shorter (7.5 hours versus 12 hours) than in their non-smoking counterparts. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (Fachinformation zu Chlordiazepoxid, Arzneimittelwechselwirkungen)

• Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (Fachinformation zu Clozapin, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Diclofenac und Misoprostol, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Diflunisal, Warnhinweise)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (Fachinformation zu Dikaliumclorazepat, Arzneimittelwechselwirkungen)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving RELPAX. (Fachinformation zu Eletriptan, Warnhinweise und Vorsichtsmaßnahmen)

Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam (see CLINICAL PHARMACOLOGY ). (Fachinformation zu Estazolam, Arzneimittelwechselwirkungen)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (Fachinformation zu Estradiol, Warnhinweise)

Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). (Fachinformation zu Estradiol und Norethisteron, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Etodolac, Warnhinweise)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Fenoprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Flurbiprofen, Warnhinweise und Vorsichtsmaßnahmen)

In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered. (Fachinformation zu Flutamid, Warnhinweise)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (Fachinformation zu Fluticason, Warnhinweise und Vorsichtsmaßnahmen)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (Fachinformation zu Fluvoxamin, Warnhinweise und Vorsichtsmaßnahmen)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan succinate. (Fachinformation zu Frovatriptan, Warnhinweise und Vorsichtsmaßnahmen)

In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. (Fachinformation zu Humaninsulin (Normalinsulin), Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Hydrocodon und Ibuprofen, Warnhinweise)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Ibuprofen und Famotidin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Indometacin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Ketoprofen, Warnhinweise)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Ketorolac, Warnhinweise und Vorsichtsmaßnahmen)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (Fachinformation zu Konjugierte Estrogene, Warnhinweise)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or VTE (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (Fachinformation zu Konjugierte Estrogene und Bazedoxifen, Warnhinweise und Vorsichtsmaßnahmen)

Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (Fachinformation zu Medroxyprogesteron, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Mefenaminsäure, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Meloxicam, Warnhinweise und Vorsichtsmaßnahmen)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (Fachinformation zu Methylergometrin, Warnhinweise)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Nabumeton, Warnhinweise)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Naproxen und Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving naratriptan tablets. (Fachinformation zu Naratriptan, Warnhinweise und Vorsichtsmaßnahmen)

WARNINGS Cigarette smoking increases the risk of serious cardiovascular disease. (Fachinformation zu Norethisteron, Warnhinweise)

This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. (Fachinformation zu Olanzapin, Arzneimittelwechselwirkungen)

This results in a mean increase in olanzapine C max following fluvoxamine administration of 54% in female nonsmokers and 77% in male smokers. (Fachinformation zu Olanzapin und Fluoxetin, Arzneimittelwechselwirkungen)

The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (Fachinformation zu Omalizumab, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Oxaprozin, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

Tobacco Smoking tobacco could enhance the metabolic clearance rate of pentazocine reducing the clinical effectiveness of a standard dose of pentazocine. (Fachinformation zu Pentazocin und Naloxon, Arzneimittelwechselwirkungen)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (Fachinformation zu Piroxicam, Warnhinweise und Vorsichtsmaßnahmen)

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (Fachinformation zu Pomalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (Fachinformation zu Propafenon, Warnhinweise und Vorsichtsmaßnahmen)

CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy [see Clinical Pharmacology ( 12.7 )] . (Fachinformation zu Propranolol, Arzneimittelwechselwirkungen)

The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking [see Clinical Studies ( 14.5 )] . (Fachinformation zu Raloxifen, Warnhinweise und Vorsichtsmaßnahmen)

Pharmacokinetic Interactions with Adempas Smoking: Plasma concentrations in smokers are reduced by 50% to 60% compared to nonsmokers. (Fachinformation zu Riociguat, Arzneimittelwechselwirkungen)

In this study, current or past smokers had an additional increased risk of overall malignancies. (Fachinformation zu Ritlecitinib, Warnhinweise und Vorsichtsmaßnahmen)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (Fachinformation zu Rizatriptan, Warnhinweise und Vorsichtsmaßnahmen)

Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking hormone replacement therapy [ see Clinical Pharmacology ( 12.3 ) ]. (Fachinformation zu Ropinirol, Arzneimittelwechselwirkungen)

Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Salsalat, Warnhinweise)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Sulindac, Warnhinweise)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving IMITREX tablets. (Fachinformation zu Sumatriptan, Warnhinweise und Vorsichtsmaßnahmen)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (Fachinformation zu Sumatriptan und Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

Cessation of Smoking: Drug Interactions: Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (Fachinformation zu Theophyllin, Warnhinweise)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Fachinformation zu Tolmetin, Warnhinweise)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

…contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan,… (Fachinformation zu Warfarin, Arzneimittelwechselwirkungen)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving zolmitriptan. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Quinidine's pharmacokinetics are also unaffected by cigarette smoking. (Fachinformation zu Chinidin, Arzneimittelwechselwirkungen)

Tobacco and other medications, have not confirmed these findings. (Fachinformation zu Chlordiazepoxid und Clidiniumbromid, Arzneimittelwechselwirkungen)

Ask a doctor before use if you have chronic cough that lasts such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. (Fachinformation zu Dextromethorphan, Warnhinweise)

Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (Fachinformation zu Dihydroergotamin, Arzneimittelwechselwirkungen)

Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (Fachinformation zu Ergotamin und Koffein, Arzneimittelwechselwirkungen)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (Fachinformation zu Heparin, Arzneimittelwechselwirkungen)

All patients had a history of heavy smoking [see Adverse Reactions (6.1) ] . (Fachinformation zu Infliximab, Warnhinweise und Vorsichtsmaßnahmen)

Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. (Fachinformation zu Naltrexon und Bupropion, Warnhinweise und Vorsichtsmaßnahmen)

This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age. (Fachinformation zu Tranexamsäure, Warnhinweise und Vorsichtsmaßnahmen)